All News
Dactylitis Indicates a Severe PsA Phenotype
A recent study analyzed the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA) and found that DMARD-naive PsA patients with dactylitis (dactylitic PsA) have a greater burden of disease than those without dactylitis.
Read Article
Apremilast’s Neutral Effects on Cardiovascular Inflammation
d
MedPage Today
An evaluation of a common psoriasis drug's effect on one cardiometabolic risk factor instead showed a favorable impact on a different one.
Read Article
Avacopan efficacy in renal failure in AAV. Appears to have benefit in renal disease that is more marked the more severe the disease is #Vasculitis22 https://t.co/3zsxjTLj62
Richard Conway RichardPAConway ( View Tweet)
The striking and most welcome streak of US Covid hospitalizations going down every single day since mid-January continues, now well below the prior pandemic nadir, and even after facing BA.2 variant dominance in parts of the country weeks ago 👍 https://t.co/WUZUCb2TOK
Eric Topol EricTopol ( View Tweet)
#ClinicalPearl Overall #azathioprine wins for maintenance of remission in ANCA associated #vasculitis with equal remission in MPO+ but less with AZA inPR3+. So use AZA but if not tolerated sometimes MMF is ok. Otherwise consider #Leflunomide or if bad organ involvement #Rituximab https://t.co/efi8cKQ36B
Janet Pope Janetbirdope ( View Tweet)
ALEVIATE - small study of Alemtuzumab (anti-CD52) in 23 refractory ANCA-Assoc vasculitis or Behcets— 16/23 (70%) had either complete (6/23, 26%) or partial (10/23, 44%) response at 6 months. 10 SAE in 7 (30%) pts https://t.co/EciG0Mkn4i https://t.co/7UmDA4NxqV
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/is2O1dewcr
Dr. John Cush RheumNow ( View Tweet)
Network metaanalysis studied 46 RCTs biologics in #PsA. Some TNFi's numerically (not signif) better vsn interleukin inhib for ACR resps, but worse on PASI resps (IL-23, IL-17i had better PASI responses); No diff in enthesitis & dactylitis resps https://t.co/AvnoLRVi6C #PsAlways https://t.co/BSl9hVbIx6
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanlysis of psychological interventions for chronic low back pain (97 RCTs, 13,136 pts) finds that Only behavioural therapy delivered w/ physiotherapy care (mainly structured exercise) reduced pain intensity up (high quality evidence) https://t.co/wHHvj0vey9 https://t.co/PBwyitTZxK
Links:
Dr. John Cush RheumNow ( View Tweet)
211 pts presenting w/ hot swollen joint to the ER; 28 w/ septic arthritis; pseudogout 32; gout 50; & others: 101. Predictors of Septic Arthritis: RA (OR 3.4); skin infx (OR 3.3); liver Dz (OR 9.9); knee involv (OR 3.5); immunosuppressive use (OR 3.5) https://t.co/uASovNVOWb https://t.co/Fq3obVDavm
Links:
Dr. John Cush RheumNow ( View Tweet)
TONIGHT! Join us for Tuesday Night Rheumatology on April 5 at 7pm ET. Register today! https://t.co/jewQ9RE88n https://t.co/EfFiztByub
Links:
Dr. John Cush RheumNow ( View Tweet)
15 RTX patients with no response to 2 doses of SARS-CoV-2 vaccine received a booster. Despite persistent B-cell depletion 7/15 had a response to booster vaccine #Vasculitis22 https://t.co/y8y8Bjnqtp
Richard Conway RichardPAConway ( View Tweet)
The BA.2 variant is now dominant in every region of the United States and accounts for 72% overall for new Covid cases
https://t.co/jjl2AnwOWX @CDCgov https://t.co/ot1GNez51W
Links:
Eric Topol EricTopol ( View Tweet)
Your Psoriatic Questions from RNL 2022
Dr. Jack Cush fields Rheumatologists questions from RNL 2022
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022.
https://t.co/DlW5KA3mEo https://t.co/wtTlYJs89l
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/PlUfbo8FNd
Dr. John Cush RheumNow ( View Tweet)
Review of 5 trials shows ixekizumab with higher rates of complete skin & nail clearance compared H2H against to etanercept, guselkumab, ustekinumab, and adalimumab (Data from IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, & SPIRIT-H2H trials https://t.co/1JjsDTZX57 #PsA #PsAlways https://t.co/H3AM4Nn2I0
Links:
Dr. John Cush RheumNow ( View Tweet)
Towards More Uniform Methotrexate Dosing in Psoriasis
https://t.co/3GrJADizKK https://t.co/jMAQO5D5Zz
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Your Rheumatoid Questions from RNL 2022
Rheumatologists questions for Dr. Jack Cush QD
Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/gNk77DIEKK https://t.co/kxJVvRnmkH
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 221 active RA pts starting a DMARD showed that Sleep disturbance significantly predicted subsequent pain sensitization and conditioned pain modulation. https://t.co/zcUVaMemXN https://t.co/5timIb0aeG
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Your Lupus Questions from RNL 2022
Rheumatologists questions for Dr. Jack Cush
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/5caTUJIYtr https://t.co/wCraFM8SwW
Links:
Dr. John Cush RheumNow ( View Tweet)